Yoon Byung Koo, Lee Dong Yun, Park Man Chul, Cho Soo Hyun, Park Hyoung Moo, Choi Young Min
Department of Obstetrics and Gynecology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Hallym University College of Medicine, Anyang, Korea.
J Korean Med Sci. 2017 Jun;32(6):992-998. doi: 10.3346/jkms.2017.32.6.992.
This study evaluated the effects of combination treatment with alendronate (ALEN) and hormone therapy (HT) on bone mineral density (BMD) in postmenopausal Korean women. This multicenter, randomized, controlled clinical trial enrolled 344 postmenopausal women with low BMD. The women received HT (0.625 mg/day of conjugated equine estrogen and 2.5 mg/day of medroxyprogesterone acetate) alone or in combination with ALEN (10 mg/day) for 1 year. Changes in BMD and biochemical markers of bone turnover were evaluated. Data from 203 women (HT alone, 99; combination treatment, 104) who completed this study were analyzed. BMD at the lumbar spine and total hip increased significantly in both treatment groups after 1 year. There were no significant differences between HT alone vs. the combination of ALEN and HT in mean BMD increase at the lumbar spine (6.9% vs. 7.9%) and total hip (3.7% vs. 3.8%). Combined therapy suppressed serum osteocalcin and urinary deoxypyridinoline to a greater extent than HT alone. In conclusion, compared to HT alone, combination treatment with ALEN and HT for 1 year did not offer a benefit in BMD in postmenopausal Korean women with low BMD.
本研究评估了阿仑膦酸钠（ALEN）与激素疗法（HT）联合治疗对绝经后韩国女性骨密度（BMD）的影响。这项多中心、随机、对照临床试验纳入了344名骨密度较低的绝经后女性。这些女性单独接受HT（每日0.625毫克结合马雌激素和每日2.5毫克醋酸甲羟孕酮）或与ALEN（每日10毫克）联合使用1年。评估了骨密度和骨转换生化标志物的变化。对完成本研究的203名女性（单独使用HT，99名；联合治疗，104名）的数据进行了分析。1年后，两个治疗组的腰椎和全髋骨密度均显著增加。单独使用HT与ALEN和HT联合使用在腰椎平均骨密度增加（6.9%对7.9%）和全髋（3.7%对3.8%）方面无显著差异。联合治疗比单独使用HT更能抑制血清骨钙素和尿脱氧吡啶啉。总之，与单独使用HT相比，ALEN和HT联合治疗1年对骨密度较低的绝经后韩国女性在骨密度方面并无益处。
